David I. Bernstein
YOU?
Author Swipe
View article: Benefits of Epinephrine for Anaphylaxis Outweigh Potential Harm—A Safety Review
Benefits of Epinephrine for Anaphylaxis Outweigh Potential Harm—A Safety Review Open
Anaphylaxis is a potentially life-threatening allergic reaction that can progress quickly, and although fatal anaphylaxis is very rare, treatment should be given as soon as possible. The recommended first-line treatment for anaphylaxis is …
View article: Transcriptome analysis in human breast milk and blood in a randomized trial after inactivated or attenuated influenza immunization
Transcriptome analysis in human breast milk and blood in a randomized trial after inactivated or attenuated influenza immunization Open
Transcriptomic signatures were identified in human peripheral blood mononuclear cells (PBMCs) and breast milk lymphocyte (BML) cells induced by trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV) admin…
View article: Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype Open
Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 ClinicalTrials.gov numbers, NCT04719832 and NCT04718103.).
View article: Small Animal Models to Study Herpes Simplex Virus Infections
Small Animal Models to Study Herpes Simplex Virus Infections Open
Herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) are two of the most prevalent human viruses worldwide. They are known to cause a variety of diseases including genital herpes, meningitis, encephalitis, cold sores…
View article: Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions
Development of neffy, an Epinephrine Nasal Spray, for Severe Allergic Reactions Open
Epinephrine autoinjectors (EAIs) are used for the treatment of severe allergic reactions in a community setting; however, their utility is limited by low prescription fulfillment rates, failure to carry, and failure to use due to fear of n…
View article: How Allergists Can Perform an Occupational History in Every Patient
How Allergists Can Perform an Occupational History in Every Patient Open
The occupational history is often neglected in the routine evaluation of new patients with asthma, chronic rhinitis, or dermatologic complaints. Such omissions are inadvertent because work-related conditions are often not prioritized. Ther…
View article: Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine Open
Background MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated approximately 50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting that efforts to improve this vaccine design might yiel…
View article: Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets
Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets Open
SMQ search criteria for identifying potential anaphylaxis related to SLIT were developed. Anaphylaxis was rare for SLIT-tablets.
View article: Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2
Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2 Open
Cross-neutralizing aptamers targeting both HSV-1 and HSV-2 were developed by selecting against the ectodomains of glycoprotein D (gD) from both viruses in parallel as well as sequentially using the SELEX method. Since gD facilitates viral …
View article: Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV
Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV Open
Herpes is a contagious life-long infection with persistently high incidence and prevalence, causing significant disease worldwide. Current therapies have efficacy against active HSV infections but no impact on the latent viral reservoir in…